Skip to navigation menu Skip to main content Skip to footer

Our Grantees

A row of glass test tubes filled with blue liquid is held in a transparent rack, with laboratory glassware and pipettes visible in the background.
A smiling older man with gray hair and glasses wearing a blue jacket stands in front of a body of water with several boats and trees in the background.
Michael O’Rand PhD, President and Chief Scientific Officer

$800,000 – Awarded January 2023

$300,000 / 2 years – Awarded 2021

$300,000 / 2 years – Awarded 2020

$300,000 / 2 years – Awarded 2019

Eppin Pharma

Durham, NC

About

Eppin Pharma is currently located in NC BioLabs, 701 West Main Street, Suite 200, Durham, NC 27701.

Michael O’Rand, PhD, is an emeritus professor in the Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, School of Medicine. Dr. O’Rand is a reproductive biologist and has more than 40 years of experience in studying mechanisms underlying fertilization. Dr. O’Rand established the in vitro fertilization laboratory in UNC School of Medicine’s North Carolina Memorial Hospital and the first “test tube” baby in North Carolina. He has 5 issued or pending patents and more than 90 peer-reviewed publications. Dr. O’Rand has an AB from the University of California at Berkeley, an MS from Oregon State University, Corvallis, Oregon and a PhD in Biology from Temple University, Philadelphia, PA.

Our Grant

MCI’s grants and investments with Eppin support Eppin Pharma reaching its goal of submitting an IND application to the FDA and entering first-in-man studies of their male contraceptive candidate, EP055. The approval of an IND will lead directly to a phase I clinical trial in the NIH contraceptive clinical trial network. Our support with Eppin covers the methodology used to quantitate EP055 in biological samples, in vitro safety screenings, and a GLP-compliant repeat-dose IV toxicity study, all with the idea that returns from MCI’s program-related investment feed back into the contraceptive development community.

Press Releases

Male Contraceptive Initiative Invests in Eppin Pharma to Support Clinical Trials for a Non-Hormonal Male Contraceptive​
January 19, 2023

Researcher Receives Second $300,000 Grant for Male Contraception
November 30, 2020​

Eppin Pharma Receives $300,000 Grant for Male Contraception
December 9th, 2019

A smiling older man with gray hair and glasses wearing a blue jacket stands in front of a body of water with several boats and trees in the background.
Michael O’Rand PhD, President and Chief Scientific Officer

$800,000 – Awarded January 2023

$300,000 / 2 years – Awarded 2021

$300,000 / 2 years – Awarded 2020

$300,000 / 2 years – Awarded 2019

Eppin Pharma

Durham, NC

About

Eppin Pharma is currently located in NC BioLabs, 701 West Main Street, Suite 200, Durham, NC 27701.

Michael O’Rand, PhD, is an emeritus professor in the Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, School of Medicine. Dr. O’Rand is a reproductive biologist and has more than 40 years of experience in studying mechanisms underlying fertilization. Dr. O’Rand established the in vitro fertilization laboratory in UNC School of Medicine’s North Carolina Memorial Hospital and the first “test tube” baby in North Carolina. He has 5 issued or pending patents and more than 90 peer-reviewed publications. Dr. O’Rand has an AB from the University of California at Berkeley, an MS from Oregon State University, Corvallis, Oregon and a PhD in Biology from Temple University, Philadelphia, PA.

Our Grant

MCI’s grants and investments with Eppin support Eppin Pharma reaching its goal of submitting an IND application to the FDA and entering first-in-man studies of their male contraceptive candidate, EP055. The approval of an IND will lead directly to a phase I clinical trial in the NIH contraceptive clinical trial network. Our support with Eppin covers the methodology used to quantitate EP055 in biological samples, in vitro safety screenings, and a GLP-compliant repeat-dose IV toxicity study, all with the idea that returns from MCI’s program-related investment feed back into the contraceptive development community.

Press Releases

Male Contraceptive Initiative Invests in Eppin Pharma to Support Clinical Trials for a Non-Hormonal Male Contraceptive​
January 19, 2023

Researcher Receives Second $300,000 Grant for Male Contraception
November 30, 2020​

Eppin Pharma Receives $300,000 Grant for Male Contraception
December 9th, 2019

Dr. Michael O'Rand & Eppin Pharma: Developing a Non-Hormonal Male Contraceptive Pill, EP055
Durham company trying to develop birth control pill for men

Publications

Michael G. O’Rand, Katherine G. Hamil, Tiffany Adevai, Mary Zelinski PLOS One April 19 2018. Inhibition of sperm motility in male macaques with EP055, a potential non-hormonal male contraceptive. https://doi.org/10.1371/journal.pone.0195953

O’Rand MG, Silva EJR, Hamil KG. Pharmacol Ther. 2016 Jan; 157:105–11 Non-hormonal male contraception: A review and development of an Eppin based contraceptive. PMID: 26593445 DOI: 10.1016/j.pharmthera.2015.11.004

Gomes AAS, Santos NCM, Rosa LR, Borges RJ, Fontes MRM, Hamil KG, O’Rand MG, Silva EJR. Interactions of the male contraceptive target EPPIN with semenogelin-1 and small organic ligands. Sci Rep. 2023 Sep 1;13(1):14382. doi: 10.1038/s41598-023-41365-1. PMID: 37658081; PMCID: PMC10474283.

Silva EJ, Hamil KG, O’Rand MG. Interacting proteins on human spermatozoa: adaptive evolution of the binding of semenogelin I to EPPIN. PLoS One. 2013 Dec 2;8(12):e82014. doi: 10.1371/journal.pone.0082014. PMID: 24312623; PMCID: PMC3846889.

Silva EJ, Patrão MT, Tsuruta JK, O’Rand MG, Avellar MC. Epididymal protease inhibitor (EPPIN) is differentially expressed in the male rat reproductive tract and immunolocalized in maturing spermatozoa. Mol Reprod Dev. 2012 Dec;79(12):832-42. doi: 10.1002/mrd.22119. Epub 2012 Nov 7. PMID: 23070980.

Eppin Pharma In the News

Meet MCI's Grantees & Fellows!

Our grantees and fellows represent some of the finest minds in the male contraception research community from around the world.

​At Male Contraceptive Initiative, we prioritize funding research that aligns with our mission of driving male contraception closer to clinical trials. We strategically allocate our resources to support a diverse range of projects, focusing on non-hormonal and reversible methods that have the potential to meet the needs of a broader population. Our goal is to catalyze progress in this field and bring innovative male birth control options to market.

Discover the innovative research being conducted by our grantees and fellows by clicking on the buttons below:

Looking for Something?

Welcome to your comprehensive resource on the future of male contraception! We have packed this site with vital information, and to help you find exactly what you need, we’ve created a detailed guide. Please use the Table of Contents on our homepage to easily navigate to the research, news, or resources that interest you most. This will ensure you can explore all of our important content with ease. You can access the Table of Contents by clicking on the button below: